Eupraxia Pharmaceuticals Inc. (EPRX) vs Galectin Therapeutics Inc. (GALT)
A side-by-side comparison of Eupraxia Pharmaceuticals Inc. and Galectin Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EPRX
Eupraxia Pharmaceuticals Inc.
$7.96HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
GALT
Galectin Therapeutics Inc.
$3.68HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
Total return — EPRX vs GALT
growth of $100 · dividends reinvested · last 2yEPRX +162.7% (+62.1%/yr)GALT +24.3% (+11.5%/yr)EPRX compounded faster over this window
EPRX GALT
EPRX vs GALT: by the numbers
- •EPRX is the larger company ($266M vs $242M market cap).
Metrics side by side
Valuation
| Metric | EPRX | GALT |
|---|---|---|
| P/B ratio | 2.62 | N/A |
Profitability
| Metric | EPRX | GALT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -38.33% | N/A |
| ROIC | -43.56% | -1718.59% |
Growth (annualized)
| Metric | EPRX | GALT |
|---|---|---|
| Total return CAGR (5Y) | N/A | 0.60% |
Go deeper
Dig into the metrics
Eupraxia Pharmaceuticals ROEGalectin Therapeutics ROEEupraxia Pharmaceuticals operating marginGalectin Therapeutics operating marginEupraxia Pharmaceuticals revenue growthGalectin Therapeutics revenue growthEupraxia Pharmaceuticals free cash flowGalectin Therapeutics free cash flow
Eupraxia Pharmaceuticals & Galectin Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.